肝脏CT与化学位移MRI鉴别乏脂性肾上腺腺瘤与肝细胞癌肾上腺转移的诊断效能
本回顾性研究纳入104例肝细胞癌患者的63个乏脂性肾上腺腺瘤和48个转移灶,评估多期肝脏CT参数与化学位移MRI鉴别两者的诊断效能。乏脂性腺瘤的非增强衰减值低于转移灶,而APW、RPW、RER及SI-index均高于转移灶(均p<.001)。RER的AUC最高(0.969),联合RER与APW达到最高敏感度73.0%。
要点
- 乏脂性腺瘤非增强CT衰减值(22.9±7.1 HU)低于HCC肾上腺转移灶(37.9±9.4 HU)。
- RER鉴别效能最佳,AUC为0.969,达到100%特异度时敏感度为63.5%。
- 联合RER与APW可将敏感度提升至73.0%。
核心结论
- 多期肝脏CT鉴别乏脂性肾上腺腺瘤与HCC肾上腺转移的效能优于化学位移MRI,联合RER与廓清参数时尤佳。
研究设计与样本
- 回顾性研究纳入2010年1月至2021年12月间接受多期肝脏CT的HCC患者,共104例(78例男性,平均年龄71.8±9.6岁),含63个乏脂性腺瘤和48个转移灶;66例患者在CT后一年内行化学位移MRI,含49个腺瘤和21个转移灶;参考标准为病理或随访。
关键影像表现/征象
- 乏脂性腺瘤的非增强CT衰减值为22.9±7.1 HU,HCC肾上腺转移灶为37.9±9.4 HU。
- 乏脂性腺瘤的APW为40.5%±12.8%,HCC肾上腺转移灶为23.7%±17.4%。
- 乏脂性腺瘤的RPW为30.0%±10.2%,HCC肾上腺转移灶为12.4%±9.6%。
- 乏脂性腺瘤的RER为329%±152%,HCC肾上腺转移灶为111%±43.0%。
- 乏脂性腺瘤的SI-index为43.3±20.7,HCC肾上腺转移灶为10.8±13.4。
诊断标准与关键数值
- 非增强CT衰减值AUC为0.894,达到100%特异度时敏感度为7.9%。
- APW的AUC为0.786,达到100%特异度时敏感度为25.4%。
- RPW的AUC为0.904,达到100%特异度时敏感度为30.2%。
- RER的AUC为0.969,达到100%特异度时敏感度为63.5%。
- SI-index的AUC为0.902,达到100%特异度时敏感度为24.5%;联合RER与APW的敏感度为73.0%。
临床应用与阅片要点
- 对HCC患者中CT衰减值>10 HU的乏脂性肾上腺病变,可测量非增强衰减值、APW、RPW、RER及SI-index辅助鉴别腺瘤与转移。
- 多期肝脏CT参数(尤其RER联合APW)对乏脂性腺瘤与HCC肾上腺转移的鉴别效能优于化学位移MRI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the diagnostic performance of multiphase hepatic CT parameters (non-contrast attenuation, absolute and relative washout ratios [APW and RPW, respectively], and relative enhancement ratio [RER]) and chemical-shift MRI (CS-MRI) for discriminating lipid-poor adrenal adenomas (with non-contrast CT attenuation > 10 HU) from metastases in patients with hepatocellular carcinoma (HCC).
METHODS: This retrospective study included HCC patients with lipid-poor adrenal lesions who underwent multiphase hepatic CT between January 2010 and December 2021. For each adrenal lesion, non-contrast attenuation, APW, RPW, RER, and signal-intensity index (SI-index) were measured. Each parameter was compared between adenomas and metastases. The area under the receiver operating characteristic curves (AUCs) and sensitivities to achieve 100% specificity for adenoma diagnoses were determined.
RESULTS: 104 HCC patients (78 men; mean age, 71.8 ± 9.6 years) with 63 adenomas and 48 metastases were identified; CS-MRI was performed in 66 patients with 49 adenomas and 21 metastases within one year of CT. Lipid-poor adenomas showed lower non-contrast attenuation (22.9 ± 7.1 vs. 37.9 ± 9.4 HU) and higher APW (40.5% ± 12.8% vs. 23.7% ± 17.4%), RPW (30.0% ± 10.2% vs. 12.4% ± 9.6%), RER (329% ± 152% vs. 111% ± 43.0%), and SI-index (43.3 ± 20.7 vs. 10.8 ± 13.4) than HCC metastases (all p < .001). AUC for non-contrast attenuation, APW, RPW, RER, and SI-index were 0.894, 0.786, 0.904, 0.969, and 0.902, respectively. The sensitivities to achieve 100% specificity were 7.9%, 25.4%, 30.2%, 63.5%, and 24.5%, respectively. Combined RER and APW achieved the highest sensitivity of 73.0%.
CONCLUSION: Multiphase hepatic CT allows for better discrimination between lipid-poor adrenal adenomas and metastases relative to CS-MRI, especially when combined with RER and washout parameters.
引用
- Nagayama Y, Hayashi H, Taguchi N, et al. Diagnostic performance of hepatic CT and chemical-shift MRI to discriminate lipid-poor adrenal adenomas from hepatocellular carcinoma metastases. Abdom Radiol (NY). 2024. PMID: 38456897. doi:10.1007/s00261-024-04228-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。